Stephan Reichl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1602484/publications.pdf

Version: 2024-02-01

51	1,891	25	43
papers	citations	h-index	g-index
53	53	53	2241
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Films based on human hair keratin as substrates for cell culture and tissue engineering. Biomaterials, 2009, 30, 6854-6866.	11.4	188
2	Diclofenac sodium delivery to the eye: In vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. International Journal of Pharmaceutics, 2008, 355, 307-313.	5.2	182
3	Keratin films for ocular surface reconstruction. Biomaterials, 2011, 32, 3375-3386.	11.4	149
4	RPMI 2650 epithelial model and three-dimensional reconstructed human nasal mucosa as in vitro models for nasal permeation studies. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 74, 290-297.	4.3	104
5	Keratin films for ocular surface reconstruction: Evaluation of biocompatibility in an in-vivo model. Biomaterials, 2015, 42, 112-120.	11.4	78
6	Cell culture models of the human cornea â€" a comparative evaluation of their usefulness to determine ocular drug absorption in-vitro. Journal of Pharmacy and Pharmacology, 2010, 60, 299-307.	2.4	75
7	Keratin film made of human hair as a nail plate model for studying drug permeation. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 78, 432-440.	4.3	63
8	An alkyl polyglucoside-mixed emulsifier as stabilizer of emulsion systems: The influence of colloidal structure on emulsions skin hydration potential. Journal of Colloid and Interface Science, 2011, 358, 182-191.	9.4	62
9	Review of Alternative Carrier Materials for Ocular Surface Reconstruction. Current Eye Research, 2014, 39, 541-552.	1.5	60
10	Human cornea construct HCCâ€"an alternative for in vitro permeation studies? A comparison with human donor corneas. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 60, 305-308.	4.3	58
11	A gold(<scp>i</scp>) biscarbene complex with improved activity as a TrxR inhibitor and cytotoxic drug: comparative studies with different gold metallodrugs. Metallomics, 2019, 11, 533-545.	2.4	58
12	The use of a porcine organotypic cornea construct for permeation studies from formulations containing befunolol hydrochloride. International Journal of Pharmaceutics, 2003, 250, 191-201.	5.2	57
13	Cultivation of RPMI 2650 cells as an in-vitro model for human transmucosal nasal drug absorption studies: optimization of selected culture conditions. Journal of Pharmacy and Pharmacology, 2012, 64, 1621-1630.	2.4	51
14	<i>In vitro</i> cell culture models to study the corneal drug absorption. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 559-578.	3.3	40
15	Development of a serum-free human cornea construct for in vitro drug absorption studies: The influence of varying cultivation parameters on barrier characteristics. International Journal of Pharmaceutics, 2011, 416, 268-279.	5.2	39
16	Prevalidation of a Human Cornea Construct as an Alternative to Animal Corneas for In Vitro Drug Absorption Studies. Journal of Pharmaceutical Sciences, 2012, 101, 2976-2988.	3.3	38
17	Toward the practical implementation of eye-related bioavailability prediction models. Drug Discovery Today, 2014, 19, 31-44.	6.4	37
18	Infected nail plate model made of human hair keratin for evaluating the efficacy of different topical antifungal formulations against Trichophyton rubrum in vitro. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 84, 599-605.	4.3	35

#	Article	IF	CITATIONS
19	Epithelial Wound Healing on Keratin Film, Amniotic Membrane and Polystyrene <i>In Vitro </i> Eye Research, 2014, 39, 561-570.	1.5	32
20	Expression of P-glycoprotein in excised human nasal mucosa and optimized models of RPMI 2650 cells. International Journal of Pharmaceutics, 2016, 508, 22-33.	5.2	32
21	Protein quantitation using various modes of high performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis, 2012, 71, 127-138.	2.8	31
22	Compounding of a topical drug with prospective natural surfactant-stabilized pharmaceutical bases: Physicochemical and in vitro/in vivo characterization $\hat{a} \in \text{``A ketoprofen case study. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 80, 164-175.}$	4.3	31
23	In vitro characterization and ex vivo surgical evaluation of human hair keratin films in ocular surface reconstruction after sterilization processing. Journal of Materials Science: Materials in Medicine, 2013, 24, 221-230.	3.6	30
24	Multidrug Resistance-Associated Protein (MRP1, 2, 4 and 5) Expression in Human Corneal Cell Culture Models and Animal Corneal Tissue. Molecular Pharmaceutics, 2014, 11, 2160-2171.	4.6	27
25	DynaMiTES – A dynamic cell culture platform for in vitro drug testing PART 2 – Ocular DynaMiTES for drug absorption studies of the anterior eye. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 126, 166-176.	4.3	27
26	mRNA Expression of Metabolic Enzymes in Human Cornea, Corneal Cell Lines, and Hemicornea Constructs. Journal of Ocular Pharmacology and Therapeutics, 2012, 28, 271-277.	1.4	25
27	Expression analysis of MDR1, BCRP and MRP3 transporter proteins in different in vitro and ex vivo cornea models for drug absorption studies. International Journal of Pharmaceutics, 2013, 441, 765-775.	5.2	25
28	Characterization of Vitamin C-Induced Cell Sheets Formed from Primary and Immortalized Human Corneal Stromal Cells for Tissue Engineering Applications. Cells Tissues Organs, 2013, 197, 283-297.	2.3	24
29	HCE-T cell-based permeability model: A well-maintained or a highly variable barrier phenotype?. European Journal of Pharmaceutical Sciences, 2017, 104, 23-30.	4.0	24
30	DynaMiTES – A dynamic cell culture platform for in vitro drug testing PART 1 – Engineering of microfluidic system and technical simulations. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 126, 159-165.	4.3	24
31	Recent progress in tight junction modulation for improving bioavailability. Expert Opinion on Drug Discovery, 2014, 9, 367-381.	5.0	19
32	Development of Acyclovir-Loaded Albumin Nanoparticles and Improvement of Acyclovir Permeation Across Human Corneal Epithelial T Cells. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 743-752.	1.4	19
33	Improved in vitro models for preclinical drug and formulation screening focusing on 2D and 3D skin and cornea constructs. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 126, 57-66.	4.3	16
34	Establishing and functional testing of a canine corneal construct. Veterinary Ophthalmology, 2008, 11, 280-289.	1.0	15
35	Activity of Multidrug Resistance-Associated Proteins $1\hat{a}\in$ (MRP1 $\hat{a}\in$ 5) in the RPMI 2650 Cell Line and Explants of Human Nasal Turbinate. Molecular Pharmaceutics, 2017, 14, 1577-1590.	4.6	15
36	Examining the Suitability of Riboflavin/UVA Treatment for Strengthening the Stromal Bioequivalent of a Human Cornea Construct. Current Eye Research, 2011, 36, 217-231.	1.5	10

#	Article	IF	CITATIONS
37	Expression analysis of human solute carrier (SLC) family transporters in nasal mucosa and RPMI 2650 cells. European Journal of Pharmaceutical Sciences, 2018, 123, 277-294.	4.0	10
38	Cell Culture Models of the Corneal Epithelium and Reconstructed Cornea Equivalents for In Vitro Drug Absorption Studies., 2008,, 283-306.		9
39	Expression of glutathione transferases in corneal cell lines, corneal tissues and a human cornea construct. International Journal of Pharmaceutics, 2016, 506, 371-381.	5.2	9
40	Cytochrome P450 Activity in ExÂVivo Cornea Models and a Human Cornea Construct. Journal of Pharmaceutical Sciences, 2016, 105, 2204-2212.	3.3	9
41	Tissue Barrier-on-Chip: A Technology for Reproducible Practice in Drug Testing. Pharmaceutics, 2022, 14, 1451.	4.5	7
42	Physicochemical investigations of native nails and synthetic models for a better understanding of surface adhesion of nail lacquers. European Journal of Pharmaceutical Sciences, 2019, 131, 208-217.	4.0	5
43	Decellularized human corneal stromal cell sheet as a novel matrix for ocular surface reconstruction. Journal of Tissue Engineering and Regenerative Medicine, 2020, 14, 1318-1332.	2.7	5
44	A unified in vitro test system for the assessment of tight junction modulators. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 142, 353-363.	4.3	4
45	Upregulation of P-glycoprotein expression by ophthalmic drugs in different corneal in-vitro models. Journal of Pharmacy and Pharmacology, 2015, 67, 605-615.	2.4	4
46	Cell sheet technology: Influence of culture conditions on in vitroâ€cultivated corneal stromal tissue for regenerative therapies of the ocular surface. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2021, 109, 1488-1504.	3.4	3
47	Dexamethasone-loaded keratin films for ocular surface reconstruction. Journal of Materials Science: Materials in Medicine, 2022, 33, 29.	3.6	3
48	New Classes of Polycationic Compounds as Preservatives for Ophthalmic Formulations. Pharmaceutical Research, 2019, 36, 11.	3.5	2
49	Microfluidic System for In Vivo-Like Drug Permeation Studies with Dynamic Dilution Profiles. Bioengineering, 2021, 8, 58.	3.5	2
50	Tissue-based in vitro and ex vivo models for ocular permeability studies. , 2016, , 309-323.		0
51	Parameter study of shipping conditions for the ready-to-use application of a 3D human hemicornea construct in drug absorption studies. International Journal of Pharmaceutics, 2018, 536, 377-387.	5.2	0